tiprankstipranks
SAB Biotherapeutics Signs Sales Deal with Cantor Fitzgerald
Market News

SAB Biotherapeutics Signs Sales Deal with Cantor Fitzgerald

SAB Biotherapeutics (SABS) has released an update to notify the public and investors about an entry into a material definitive agreement.

Pick the best stocks and maximize your portfolio:

SAB Biotherapeutics, Inc. entered into a sales agreement with Cantor Fitzgerald & Co. to potentially sell up to $20 million of its common stock through at-the-market offerings. The sales are at the discretion of the company and will be conducted in compliance with the Securities Act and Nasdaq regulations. The proceeds are intended for pipeline development and general corporate purposes. The company agreed to pay the agent a 3% commission on sales, and either party can terminate the agreement with prior notice.

For further insights into SABS stock, check out TipRanks’ Stock Analysis page.

Related Articles
Michael MarcusThese 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
TheFlyCraig-Hallum bullish on SAB Biotherapeutics, initiates with a Buy
TheFlySAB Biotherapeutics initiated with a Buy at Craig-Hallum
Go Ad-Free with Our App